After a slow 2024, the biotech shell company Concentra Biosciences is back, offering to buy four biotechs in the past month ...

Discover why some biotechs fail but survive with cash on hand, and how players like Concentra are trying to unlock trapped ...

GSK’s cobolimab has become the latest anti-TIM-3 antibody to flunk a crucial oncology test, as the pharma absorbs a more than $600 million hit from its anti-TIGIT drug failure. | GSK’s ...

It is no longer investing in the anti-TIGIT antibody belrestotug, which it was developing alongside iTeos Therapeutics. The pharma in May broke off its engagement with the Massachusetts-based biotech ...